Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$101,868
+$2,581 QoQ
Shares Held
650
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#1,374
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Murphy & Mullick Capital Management Corp holds $5,242,469 across 11 Drug Manufacturers - General names. NVS ranks #9 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,416 | $1,698,393 | |
| 2 | MRK |
Merck & Co., Inc.
|
11,473 | $1,474,280 | |
| 3 | PFE |
Pfizer Inc
|
19,904 | $479,288 | |
| 4 | JNJ |
Johnson & Johnson
|
1,730 | $439,368 | |
| 5 | AZN |
Astrazeneca PLC
|
2,047 | $388,152 | |
| 6 | NVO |
Novo Nordisk A S
|
5,511 | $264,197 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,957 | $228,002 | |
| 8 | ABBV |
AbbVie Inc.
|
522 | $131,356 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $101,868 | 650 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $99,287 | 650 | Shares | Sole | 2026-04-17 | |
| 2025-12-31 | $89,615 | 650 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $83,356 | 650 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $78,656 | 650 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $72,462 | 650 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $63,251 | 650 | Shares | Sole | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||